

**Supplementary Table 2.** Baseline characteristics (safety analysis set)

Variable	Safety analysis set (n=3,231)
Age, yr	56.66 ± 11.60
<65	2,402 (74.34)
≥65	829 (25.66)
<75	3,069 (94.99)
≥75	162 (5.01)
Male sex	1,851 (57.29)
BMI, kg/m <sup>2</sup>	27.26 ± 4.08
<25	809 (31.08)
≥25	1,794 (68.92)
Height, cm	164.80 ± 8.98
Weight, cm	74.12 ± 13.91
Duration of diabetes, yr	7.37 ± 7.29
<4	1,400 (43.33)
≥4 to <8	596 (18.45)
≥8	1,235 (38.22)
Smoking status	
Never smoked	2,096 (64.87)
Ex-smoker	559 (17.30)
Currently smokes	576 (17.83)
HbA1c, %	7.98 ± 1.40
FPG, mg/dL	164.81 ± 56.51
SBP, mm Hg	129.72 ± 15.18
DBP, mm Hg	77.85 ± 10.76
eGFR, mL/min/1.73 m <sup>2</sup>	93.08 ± 21.35
<60	0
≥60 to <90	1,547 (49.58)
≥90 to <120	1,243 (39.84)
≥120	330 (10.58)

(Continued to the next)

**Supplementary Table 2.** Continued

Variable	Safety analysis set (n=3,231)
Kidney disease	107 (3.31)
Liver disease	401 (12.41)
Diabetic complications	937 (29.00)
Retinopathy	374 (11.58)
Neuropathy	474 (14.67)
Nephropathy	73 (2.26)
Vasculopathy	253 (7.83)
Other disease	3,038 (94.03)
Hypertension	2,036 (63.01)
Dyslipidemia	2,232 (69.08)
Coronary artery disease	1,101 (34.08)
Stroke	157 (4.86)
Other anti-diabetic drug	3,100 (95.95)
Metformin	2,761 (85.45)
Sulfonylurea	900 (27.86)
DPP4 inhibitor	542 (16.77)
Pioglitazone	119 (3.68)
Insulin	524 (16.22)
Others	857 (26.52)
Dose of study drug, mg	
10	2,906 (89.94)
>10	325 (10.06)

Values are presented as mean ± standard deviation or number (%). BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; DPP4, dipeptidyl peptidase 4.